SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant) Neutralizing Antibody
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Delta B.1.617.2 Variant) Neutralizing Antibody is a recombinant Human Monoclonal Antibody against SARS-CoV-2/COVID-19 Spike Protein RBD (Delta B.1.617.2 Variant).
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The B.1.617.2 (Delta) variant was first identified in India. It contains the L452R and T478K mutations, which appear to increase viral infectivity compared with other variants.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The B.1.617.2 (Delta) variant was first identified in India. It contains the L452R and T478K mutations, which appear to increase viral infectivity compared with other variants.
| Supplier | Abbexa Ltd. |
|---|---|
| Product # | abx376487-50UG |
| Pricing | 50 µg USD $282.75 |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Host | Human |
| Dry Ice | No |
| Availability | Shipped within 5-10 working days. |
| Note |
|